Nuvectis Pharma
NVCT
62 hedge funds and large institutions have $34.9M invested in Nuvectis Pharma in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 1 closing their positions.
15,700% more call options, than puts
Call options by funds: $158K | Put options by funds: $1K
1,600% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 1
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
29% more funds holding
Funds holding: 48 → 62 (+14)
9% more capital invested
Capital invested by funds: $32M → $34.9M (+$2.91M)
0.42% more ownership
Funds ownership: 16.55% → 16.97% (+0.42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$672K |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$561K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$259K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$250K |
| 5 |
OCM
Occam Crest Management
Darien,
Connecticut
|
+$233K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$247K |
| 2 |
Barclays
London,
United Kingdom
|
-$180K |
| 3 |
BlackRock
New York
|
-$157K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$96.9K |
| 5 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
-$94.2K |
NVCT Hedge Fund Activity: Q1 2026 in Review
62 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q1 2026, worth a combined $34.9M — up 9.1% from $32M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NVCT positions and 1 closed out — a net gain of 16 holders — while 20 added to existing stakes and 9 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $672K. The largest seller was Susquehanna International Group, cutting an estimated $247K.
- 62 institutional investors held Nuvectis Pharma (NVCT) as of Q1 2026, up from 48 in Q4 2025.
- Funds reported $34.9M of Nuvectis Pharma stock for Q1 2026, up 9.1% quarter-over-quarter.
- 17 funds opened new Nuvectis Pharma positions in Q1 2026 and 1 closed out, a net change of +16 holders.
- The largest Nuvectis Pharma buyer in Q1 2026 was Citadel Advisors, an estimated $672K added.
- The largest Nuvectis Pharma seller in Q1 2026 was Susquehanna International Group, an estimated $247K sold.
Based on aggregated 13F filings for Q1 2026.